ISSN: 2161-1149 (Printed)
+44-77-2385-9429
Department of Rheumatology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina
Dr Enrique Soriano is Head of Rheumatology at Hospital Italiano de Buenos Aires, Argentina.Dr. Soriano earned his medical degree from the University of Buenos Aires School of Medicine in 1982. He then went on to complete his residency training in internal medicine and specialize in rheumatology at Hospital Italiano de Buenos Aires, and completed a fellowship at the Royal National Hospital for Rheumatic Diseases, in Bath UK. Dr. Soriano completed his MS degree in clinical effectiveness at the University of Buenos Aires.
Research Article
Metothrexate Plus Leflunomide Step-Up Therapy in Early Rheumatoid Arthritis Patients with Non-Response to Initial Methotrexate Monotherapy
Author(s): Carlevaris L*, Citera G, Pellet C, Manzano M, Amaya CG, Martire MV, Bennasar G, Secco A, Landi M, Del Para F, Waimann CA, Ceccato F, Paira S, Caeiro F, Salinas HMJ, Benzaquen N, Pirola J, Soriano ER, Bertiller E, Rosa J, Marcos J, García MA, Costi AC, Muñoz MA, Rillo O, Berman H, Berman A, Colombres F, Velozo EJ, Juarez V, Crespo M, Quinteros A, Leal M, Salvatierra G, Ledesma C, Sacnún M, Quintana R and Abdala M
Methods: We included a cohort of patients with diagnosis of early RA of less than 2 years of disease duration who not respond to MTX monotherapy, according to medical judgment, and added step-up combination with LEF. Data were collected every 3 months, including sociodemographic characteristics, functional status, disease activity and treatment. The primary outcome was the time to remission with the combined therapy, defined according to disease activity index of 28 joints (DAS28). Combination treatment failure was defined as not achieving remission. Time of outcome was assessed from date of the start of MTX plus LEF combination to date of remission or last follow-up. The Kaplan-Meier product limit method was used to estimate the probability of each outcome.
Results: A total of 106 patients were included. The median disease duration was 4 (I.. View More»
DOI:
10.35248/2161-1149.19.9.249